Ronald S. Walters, M.D., MBA, MHA
Department of Breast Medical Oncology, Division of Cancer Medicine
About Dr. Ronald S. Walters
Ron Walters is an associate vice president of medical operations and informatics at The University of Texas MD Anderson Cancer Center in The Texas Medical Center, applying more than 30 years of experience and knowledge here at MD Anderson.
Dr. Walters is a breast medical oncologist and has direct responsibility for the Tumor Registry, the Transfer Center, Managed Care Programs, and assists with our physician training course in quality, the Clinical Safety and Effectiveness Course, ICD-10 implementation and coding documentation improvement efforts, and our response to federal reporting requirements under the Affordable Care Act. He is a founding member of the Measures Application Partnership of the National Quality Forum. He serves on multiple institutional, state and federal committees striving for improvements in patient care, research and our support systems.
Dr. Walters completed his MBA at the University of Houston. When he realized it was too general for health care, he completed a Masters in Health Administration, followed by Masters in the management of computing and information systems.
It was through these programs that he learned to appreciate that a more complete perspective was obtained if you had some hands-on experience in the profession combined with formal education. Dr. Walters’ considers himself a productive member of a great team with great leadership at MD Anderson Cancer Center.
Present Title & Affiliation
Primary Appointment
Professor of Clinical Medicine, Non-Tenured, Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Professor of Clinical Medicine, Non-Tenured, Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Healthcare reform and system changes to improve quality
Cost accounting in healthcare, specifically the application of TDABC to hospitals.
Education & Training
Degree-Granting Education
| 2000 | Houston Baptist University, Houston, Texas, US, Management of Computing and Information Svcs, M.S |
| 1998 | Houston Baptist University, Houston, Texas, US, Healthcare Administration, MHA |
| 1996 | University of Houston, Houston, Texas, US, General Business Administration, MBA |
| 1976 | University of Nebraska College of Medicine, Omaha, Nebraska, US, MD |
| 1973 | University of Nebraska, Lincoln, Nebraska, US, Math, BS |
Postgraduate Training
| 1979-1981 | Fellowship in Developmental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 1976-1979 | Residency in Internal Medicine, Louis A. Weiss Memorial Hospital, Chicago, Illinois |
Licenses & Certifications
| 2023 | State of Alabama Medical License |
| 2022 | Washington State Department of Health |
| 2021 | State of Tennessee Department of Health |
| 1987 | Medical Oncology |
| 1981 | Texas |
| 1979 | Internal Medicine |
Experience & Service
Faculty Academic Appointments
Associate Professor of Clinical Medicine, Non-Tenured, Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, 2000 - 2005
Associate Professor of Clinical Medicine, Non-Tenured, University of Texas M. D. Anderson Cancer Center, Houston, TX, 1987 - 1996
Assistant Professor of Clinical Medicine, Non-Tenured, University of Texas M. D. Anderson Cancer Center, Houston, TX, 1983 - 1987
Assistant Instructor of Medicine, Non-Tenured, University of Texas M. D. Anderson Cancer Center, Houston, TX, 1981 - 1983
Administrative Appointments/Responsibilities
Chair MD Faculty Bylaws Committee, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2019 - 2022
Committee Chair, PRS Clinical Revenue Cycle, The University of Texas MD Anderson Cancer Center, Houst, TX, 2013 - Present
Medical Director, Transfer Center, Ofc/EVP, Physician-in-Chief, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2019
Medical Director, Clinical Operations, University of Texas M.D. Anderson Cancer Center, Houston, TX, 2005 - 2006
Medical Director, CSE Course, The University of Texas MD Anderson Cancer Center, Houston, TX, 2004 - 2015
Medical Director, Medical Informatics, University of Texas M.D. Anderson Cancer Center, Houston, TX, 2004 - 2006
Medical Director, Physicians Network, University of Texas M.D. Anderson Cancer Center, Houston, TX, 2000 - 2008
Other Professional Positions
Chair, Board of Directors, NCCN, PHiladelphia, PA, 2019 - 2022
President Elect, Harris County Medical Society, Houston, 2019 - 2020
Chair National Quality Partnership, National Quality Forum, Washington, DC, 2019 - 2019
Member MAP Coordinating Committee, National Quality Forum, Washington, DC, 2018 - 2022
Chair Bylaws Committee, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2022
Chair Payment and Policy TAsk Force, National Quality Forum, Washington, DC, 2018 - 2021
Member Task Force Healthcare System Reform, National Quality Forum, WAshington, DC, 2018 - 2020
Member, Shared Decision Making Workgroup, National Quality Partnership, Washington, DC, 2017 - 2018
Member, NCCN Quality and Outcomes Committee, NCCN, Philadelphia, PA, 2016 - Present
Member, Board, Texas Medical Foundation Quality Improvement Organization, Austin, TX, 2016 - 2022
Member, NCCN Quality and Outcomes Steering Committee, Philadelphia, PA, 2016 - Present
Member, NCCN Executive Committee of the Board, Philadelphia, PA, 2016 - Present
Member, National Quality Partnership Leadership Consortium, Washington, DC, 2016 - Present
Member, National Quality Partners Measure Incubator Steering Committee, Washington, DC, 2016 - 2018
Chair, MAP, National Quality Forum, Washington DC, 2016 - 2019
Member, Value Work Group, NCCN, Philadelphia, PA, 2015 - 2017
Member, Investment Committee, Harris County Medical Society, Houston, TX, 2015 - 2021
Member, Advance Illness Care Action Team, National Quality Partnership, Washington, DC, 2015 - 2017
Member, Cancer Center Directors Panel, NCCN, Philadelphia, PA, 2015 - 2017
Member, Advisory Committee, US News and World Report, Washington, DC, 2015 - 2016
Member, National Quality Foroum Scientific Methods Panel, Washington, DC, 2015 - Present
Member, Texas Medical Association MOC Task Force, Austin, TX, 2015 - 2017
Member, National Quality Forum MAP Affordability Taskforce, Washington, DC, 2014 - 2014
Member, Physician Advisory Committee, Alliance of Dedicated Cancer Centers, Washington, DC, 2014 - Present
Quality Measures, Texas Institute of Health Care Quality, Austin, TX, 2014 - 2015
Member, Guidelines Steering Committee, NCCN, Philadelphia, PA, 2014 - Present
MAP Affordability Task Force, National Quality Forum, Washington, DC, 2014 - 2015
Vice-Chair MAP Measures Application Partnership, National Quality Forum, Washington, DC, 2014 - 2016
Member, Quality Reporting Committee, TIHQE - Texas Institute of Healthcare Quality and Efficiency, Austin, TX, 2013 - 2016
Ad-Hoc Member, CIO Committee, Alliance of Dedicated Cancer Centers, Houston, TX, 2013 - 2015
Member, AMA PCPI Physicians Consortium for Performance Improvement, AMA - American Medical Association, Chicago, IL, 2013 - 2015
Member, Medicare Carrier Advisory Committee, Texas Society of Clinical Oncology, Dallas, TX, 2012 - Present
Member, Board of Directors, NCCN - National Comprehensive Cancer Network, Philadelphia, PA, 2012 - Present
Member/Invited Consultant, Texas Medical Association Quality Council, Houston, TX, 2012 - 2018
Chair/Member, Harris County Medical Society Quality Committee, Houston, TX, 2012 - 2015
Member, Texas Medical Association Subcommittee for Academic Physicians and Council on Medical Education, Houston, TX, 2012 - 2015
Member, Texas Medical Association Council of Socioeconomics, Houston, TX, 2012 - 2013
Member, Quality Based Payment Advisory Committee, State of Texas HHSC - Medicaid, Austin, TX, 2012 - 2016
Member Quality Committee, Alliance of Dedicated Cancer CEnters, New York, NY, 2011 - Present
Fellow UT CSE Course, University of Texas System, Austin, TX, 2011 - 2018
Faculty Advisor - Advanced Medical Leadership Course, UT School Public Health, Houston, TX, 2011 - 2016
Member, Value Committee, Alliance of Dedicated Cancer Center, Houston, TX, 2011 - 2014
Ad-Hoc Member, Executive Committee, Alliance of Dedicated Cancer Centers, Houston, TX, 2011 - 2013
Delegate, Texas Medical Association, Houston, TX, 2010 - Present
Member, C4QI Comprehensive Cancer Center Committee for Quality Improvement, Houston, TX, 2010 - Present
Member, Best Practice Committee, NCCN, Philadelphia, PA, 2010 - Present
Member, Measure Application Partnership, National Quality Forum, Washington, DC, 2010 - Present
Board of Directors, Harris County Medical Society, Houston, 2010 - 2021
Fellow, Clinical Safety and Effectiveness, University of Texas MD Anderson, Houston, TX, 2010 - 2018
Vice Chair Quality Committee, Alliance of Dedicated Cancer Centers, Houston, TX, 2010 - 2014
Chair, Board of Socioeconomics, Harris County Medical Society, Houston, TX, 2009 - 2011
Clinical Practice Subcommittee, American Society of Clinical Oncology, Houston, TX, 2006 - 2008
Member, Medical Directors Committee, Harris County Medical Society, Houston, TX, 2005 - 2009
Alternate Delegate, Texas Medical Association, Houston, TX, 2005 - 2006
Member, Board of Medical Legislation, Harris County Medical Society, Houston, TX, 2004 - 2009
Chair, Medicaid Forum, Harris County Medical Society, Houston, TX, 2004 - 2008
Member, Board of Socioeconomics, Harris County Medical Society, Houston, TX, 2004 - 2006
Member, Telehealth Committee, University of Texas Medical Branch, Houston, TX, 2003 - 2006
Member, Managed Care Committee, Harris County Medical Society, Houston, TX, 2002 - 2008
Member, Credentials Committee, University of Texas Medical Branch Galveston Healthcare Systems, Galveston, TX, 2002 - 2006
Member, Quality Improvement Committee, University of Texas Medical Branch Galveston Healthcare Systems, Galveston, TX, 2000 - 2006
Extramural Institutional Committee Activities
Member, ECOT Finance Committee, The University of Texas MD Anderson Cancer Center, 2016 - 2017
Member, Utilization Review Subcommittee, The University of Texas MD Anderson Cancer Center, 2016 - Present
Associate Head, Institute of Cancer Care Innovation, The University of Texas MD Anderson Cancer Center, 2016 - Present
Member, MACRA Steering Committee, The University of Texas MD Anderson Cancer Center, 2015 - Present
Member, MDACC Strategic Pricing Committee, The University of Texas MD Anderson Cancer Center, 2015 - Present
Member, Medical Quality Planning Committee, The University of Texas MD Anderson Cancer Center, 2015 - 2018
Chair, United Healthcare Bundled Pilot Implementation, The University of Texas MD Anderson Cancer Center, 2014 - 2017
Member, PRS Steering and Strategy for Reporting, The University of Texas MD Anderson Cancer Center, 2014 - Present
Sponsor, ICD-10 Implementation Project, The University of Texas MD Anderson Cancer Center, 2014 - 2016
Member, Clinical Business Enterprise and Innovation BOV Advisory Committee, The University of Texas MD Anderson Cancer Center, 2014 - 2018
Member, Time Driven Activity Based Costing Committee, The University of Texas MD Anderson Cancer Center, 2014 - 2016
Member, Clinical Revenue Billing Task Force, The University of Texas MD Anderson Cancer Center, 2014 - 2016
Member, Formulary Management Evaluation Team, The University of Texas MD Anderson Cancer Center, 2013 - Present
Member, Executive Research Billing Compliance Committee, The University of Texas MD Anderson Cancer Center, 2012 - Present
Ad hoc Member, PRS Executive Committee, The University of Texas MD Anderson Cancer Center, 2010 - Present
Chair, PRS Clinical Revenue Cycle Committee, The University of Texas MD Anderson Cancer Center, 2009 - Present
Member, Steering Committee, UT System Clinical Safety and Effectiveness Course, The University of Texas MD Anderson Cancer Center, 2009 - 2017
Member, Patient Financial Screening Review, The University of Texas MD Anderson Cancer Center, 2008 - 2008
Member, Managed Care A-Team, The University of Texas MD Anderson Cancer Center, 2008 - Present
Member, Comprehensive Cancer Plan Executive Steering Committee, The University of Texas MD Anderson Cancer Center, 2008 - 2012
Member, Comprehensive Cancer Data and Prioritization Workgroup, The University of Texas MD Anderson Cancer Center, 2008 - 2012
Member, Project Bed Executive Team, The University of Texas MD Anderson Cancer Center, 2008 - 2011
Member, Quality Operations Team, The University of Texas MD Anderson Cancer Center, 2008 - 2011
Board of Directors, MDACC Physicians Network, The University of Texas MD Anderson Cancer Center, 2008 - 2010
Member, Senior Clinical Operations Team, The University of Texas MD Anderson Cancer Center, 2005 - 2013
Member, Executive Billing Compliance Committee, The University of Texas MD Anderson Cancer Center, 2004 - Present
Member, Council of Committee Chairmen, The University of Texas MD Anderson Cancer Center, 2004 - 2013
Deputy Chair, Clinical Operations IT Project Steering Workgroup, The University of Texas MD Anderson Cancer Center, 2004 - 2011
Member, Pharmacy Project Steering Committee, The University of Texas MD Anderson Cancer Center, 2004 - 2006
Member, Electronic Medical Record Steering Committee, The University of Texas MD Anderson Cancer Center, 2004 - 2006
Member, JCAHO Medical Staff Standards Focus Group, The University of Texas MD Anderson Cancer Center, 2004 - 2006
Member, Charge Capture Subcommittee, The University of Texas MD Anderson Cancer Center, 2004 - 2006
Member, Uncompensated Charity Care Committee, The University of Texas MD Anderson Cancer Center, 2003 - Present
Documentation and Coding Workgroup, USNWR Task Force, The University of Texas MD Anderson Cancer Center, 2003 - 2017
Member, Medical Practice Subcommittee, The University of Texas MD Anderson Cancer Center, 2003 - 2017
Member, JCAHO Executive Steering Committee, The University of Texas MD Anderson Cancer Center, 2003 - 2013
Deputy Chair, Revenue Cycle Advisory Committee, The University of Texas MD Anderson Cancer Center, 2003 - 2008
Member, Executive Internet Steering Committee, The University of Texas MD Anderson Cancer Center, 2003 - 2008
Member, Patient Education Executive Steering Committee, The University of Texas MD Anderson Cancer Center, 2003 - 2007
Member, Involved Provider Database Steering Committee, The University of Texas MD Anderson Cancer Center, 2003 - 2006
Member, ACB Activation Subcommittee, The University of Texas MD Anderson Cancer Center, 2003 - 2004
Member, Institutional Patient Safety Committee, The University of Texas MD Anderson Cancer Center, 2002 - 2014
Member, Quality Council, The University of Texas MD Anderson Cancer Center, 2002 - 2010
Member, Executive Advisory Panel, The University of Texas MD Anderson Cancer Center, 2002 - 2010
Member, Information Systems Security Committee, The University of Texas MD Anderson Cancer Center, 2002 - 2004
Member, Information Systems Steering Committee, The University of Texas MD Anderson Cancer Center, 2002 - 2004
Member, Clinical Computing Advisory Group, The University of Texas MD Anderson Cancer Center, 2002 - 2003
Member, MOSAIC Executive Steering Committee, The University of Texas MD Anderson Cancer Center, 2001 - 2004
Member, M.D. Anderson Physicians Network Credentials Committee, The University of Texas MD Anderson Cancer Center, 2000 - Present
Member, M.D. Anderson Physicians Network Quality Improvement Committee, The University of Texas MD Anderson Cancer Center, 2000 - 2017
Chairman, M.D. Anderson Physicians Network Utilization Management Committee, The University of Texas MD Anderson Cancer Center, 2000 - 2002
Member, Quality Improvement Committee, The University of Texas MD Anderson Cancer Center, 2000 - 2001
Chairman, Ethics Committee, The University of Texas MD Anderson Cancer Center, 1999 - 2000
Member, Executive Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, 1998 - 2000
Member, Patient Care Committee, The University of Texas MD Anderson Cancer Center, 1998 - 2000
Member, Medical Records Committee, The University of Texas MD Anderson Cancer Center, 1998 - 2000
Member, Ethics Committee, The University of Texas MD Anderson Cancer Center, 1997 - 2000
Member, Cancer Committee, The University of Texas MD Anderson Cancer Center, 1996 - 1998
Member, Surveillance Committee, The University of Texas MD Anderson Cancer Center, 1994 - 1996
Member, Medical Records Committee, The University of Texas MD Anderson Cancer Center, 1985 - 1987
Member, Utilization Review Committee, The University of Texas MD Anderson Cancer Center, 1985 - 1987
Member, Patient Education Committee, The University of Texas MD Anderson Cancer Center, 1983 - 1985
Member, Ethics Committee, The University of Texas MD Anderson Cancer Center, 1983 - 1985
Honors & Awards
| 2020 - 2021 | President, Harris County Medical Society |
| 2018 | NCCN Board of Producers, NCCN |
| 1971 | Phi Eta Sigma, University of Nebraska |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2022. Value Based Cancer Care. Conference. UTMDACC. Houston, TX, US.
- 2017. Safety and Quality in the Network. Conference. MDACC. Houston, TX, US.
- 2014. Quality Measurement in Oncology. Conference. MDAPN. Houston, TX, US.
- 2014. Quality Measurement in Integrative Medicine. Conference. Society of Integrative Oncology. Houston, TX, US.
- 2014. Hematology Oncology and Healthcare Reform. Conference. UTMDACC. Houston, TX, US.
- 2013. ICD-10. Conference. Houston Area Medical Informatics. Houston, TX, US.
- 2013. ICD10 and Coding. Conference. Texas Tumor Registry Association. Houston, TX, US.
- 2013. Value Based healthcare. Conference. Texas Society of Clinical Oncology. Houston, TX, US.
- 1995. Oncologic Emergencies. Invited. AACCN. Houston, TX, US.
Regional Presentations
- 2022. Value BAsed Cancer Care. Conference. Global Media Dynamics. Las Vegas, NV, US.
- 2016. Quality Based Payment and MACRA. Conference. TMA. Austin, TX, US.
- 2016. MACRA Update. Conference. TMA. Austin, TX, US.
- 2016. MACRA Webinar. Conference. TMA. Austin, TX, US.
- 2016. Physician Compensation Based on Patient Satisfaction Surveys. Conference. TMA. Dallas, TX, US.
- 2016. Value Based Care. Conference. TMA. Dallas, TX, US.
- 2016. MACRA and you. Conference. TMA. Dallas, TX, US.
- 2015. United Healthcare Bundled Payment Pilot. Conference. Global Media Dynamics. Las Vegas, NV, US.
- 2015. Value Based Care. Conference. Texas Medical Association. Austin, TX, US.
- 2014. Quality Measurement. Conference. Texas Scottish Rite Hospital - Dallas. Dallas, TX, US.
- 2014. PQRS. Conference. TMA. Austin, TX, US.
- 2014. Choosing Wisely. Conference. Texas Medical Association. Austin, TX, US.
- 2014. Measuring Patient Reported Outcomes. Conference. MDACC, TX, US.
- 1991. Breast Cancer. Invited. Breast Cancer. Waco, TX, US.
- 1990. CIBA-GEIGY. Invited. CIBA-GEIGY. Dallas, TX, US.
National Presentations
- 2019. Alternative Payment Models. Invited. Scottscale, AZ, US.
- 2019. Oncology Policy Summit. Invited. NCCN. Washington, DC, US.
- 2019. CAncer Policy. Invited. WAshington, DC, US.
- 2019. Patient Centered Care in Cancer. Invited. Washington, DC, US.
- 2019. Alternative Payment Models in Cancer. Invited. New Orleans, LA, US.
- 2018. Bundled Payments in Oncology. Invited. Las Vegas, NV, US.
- 2018. Value Based Reimbursement. Conference. HICOR Fred Hutchinson. Seattle, WA, US.
- 2017. Successful Strategies in Implementing Effective Oncology Bundled Payment Models. Invited. 7th Annual Bundled Payments Congress. Las Vegas, NV, US.
- 2017. How Bundled Payments Affect Hospitals and Physician Leaders. Conference. 7th Annual Bundled Payments Congress. Las Vegas, NV, US.
- 2017. Redefining Quality Measurement in Oncology. Conference. NCCN. Washington, DC, US.
- 2017. Value Demonstration in Oncology. Conference. Denver, CO, US.
- 2017. Value Based Healthcare in Cancer. Conference. 2017 Value Based Healthcare Congress. Las Vegas, NV, US.
- 2017. Advanced Illness Care. Conference. National Quality Partnership. Washington, DC, US.
- 2016. Alternative Payment Models at MDACC. Invited. Global Media Dynamics. New Orleans, LA, US.
- 2016. Quality Measure Development. Invited. Walters. San Diego, CA, US.
- 2016. UHC Bundled Payment Pilot. Invited. Walters. Memphis, TN, US.
- 2015. Advance Illness Care Webinar. Invited. National Quality Forum. Washington, DC, US.
- 2015. United Healthcare Bundled Payment Pilot. Invited. 2015 Healthcare Bundled Payments Congress. Scottsdale, AZ, US.
- 2015. Providing Value to the Patient. Conference. NCCN Academy for Leadership in Oncology. Berkeley, CA, US.
- 2015. Leadership in Oncology. Conference. Walters. Philadelphia, PA, US.
- 2015. Bundled Payment Pilot at MDACC. Invited. Brookings Institute. Washington, DC, US.
- 2015. High Quality Cancer Care. Invited. American Board of Quality Assurance and Utilization Review. Houston, TX, US.
- 2015. Value in Cancer Care NCCN Annual Conference. Invited. NCCN. Hollywood, FL, US.
- 2014. The Future of Oncology. Invited. UTMDACC Partners. Houston, TX, US.
- 2014. Healthcare Reform and Integrative Medicine. Invited. Society for Integrative Oncology. Houston, TX, US.
- 2014. Strategies for Activating Physicians. Invited. American Medical Association. Chicago, IL, US.
- 2014. Innovations in Providing Quality Cancer Care. Invited. Texas Society of Clinical Oncology. San Antonio, TX, US.
- 2014. The ACA and NCCN Institutions. Invited. NCCN. Philadelphia, PA, US.
- 2014. Health Reform and Payment. Invited. Washington, DC, US.
- 2014. Measuring Affordable Care Expert Panel. Conference. National Quality Forum. Washington, DC, US.
- 2013. Opportunities for Improvement. Conference. NCCN. Ann Arbor, MI, US.
- 1990. Title not provided. Invited. Bone Metastases: Pathology, Diagnosis and Treatment. Houston, TX, US.
- 1990. AACR. Invited. AACR. Washington, US.
- 1986. AACR. Invited. AACR. Los Angeles, CA, US.
- 1985. Title not provided. Invited. “The Current Status of Navantrone” Symposium. Scottsdale, AZ, US.
International Presentations
- 2015. Value in Provider-Payer Relationships. Conference. ASCO. Alexandria, US.
- 2013. Cancer Readmission. Invited. ASCO. San Diego, US.
Formal Peers
- 2018. NCCN Oncology Policy Summit. Invited. Washington, DC, US.
- 2018. Value in Cancer CAre Summit. Invited. Seattle, WA, US.
- 2015. Alternative Payment Models. Visiting. Austin, TX, US.
- 2014. Legal Obstacles to Value Based Purchasing. Visiting. Houston, TX, US.
- 2014. Value Based Healthcare. Invited. Dallas, TX, US.
- 2014. Bundled Payment in Healthcare. Invited. Boston, MA, US.
- 2014. Academic Structure and Politic. Invited. Houston, TX, US.
- 1998. Taxotere Speakers Training Program. Invited. Phoenix, AZ, US.
- 1997. Smith-Kline-Beecham Advisory Committee Meeting. Invited. San Antonio, TX, US.
- 1996. Taxotere Consultants Advisory Meeting. Invited. Chicago, IL, US.
- 1990. Hillcrest Baptist Medical Center Tumor Board Conference, Breast Cancer. Invited. Waco, TX, US.
- 1989. Gallium Nitrate Investigators Meeting for Cancer Indications - Bone Metastases, Hypercalcemia. Invited. Chicago, IL, US.
- 1986. New Developments in Bone Marrow Transplantation. Invited. San Francisco, CA, US.
Grant & Contract Support
| Date: | 2006 - 2009 |
| Title: | Assessing Problem Areas in Referrals for Chronic Hematological Malignancies and Developing Interventions to Address Them |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 12-312-0208633 01 |
Selected Publications
Peer-Reviewed Articles
- Gallo L, Walters RS, Allen J, Ahlstrom J, Alspach C, Biru Y, Schatz A, Martin K, Carlson RW. Accelerating Advances in Cancer Care Research: A Lookback at the 21st Century Cures Act in 2020. J Natl Compr Canc Netw 19(4):378-384, 2021. e-Pub 2021. PMID: 33845456.
- NQF. 2020 Annual Report to Coingress, 2021. e-Pub 2021.
- Bandini LAM, Gallo L, Johnson T, Martin K, Schatz AA, Adelson K, Loy BA, Walters RS, Wong T, Carlson RW. NCCN Policy Summit: Defining, Measuring, and Applying Quality in an Evolving Health Policy Landscape and the Implications for Cancer Care. J Natl Compr Canc Netw 18(7):820-824, 2020. e-Pub 2020. PMID: 32634773.
- Forum NQ. 2019 Annual Report to Congress, 2020. e-Pub 2020.
- Yam C, Murthy RK, Rauch GM, Murray JL, Walters RS, Valero V, Brewster AM, Bast RC Jr, Booser DJ, Giordano SH, Esteva FJ, Yang W, Hortobagyi GN, Moulder SL, Arun B. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-beta. Invest New Drugs 36(6):1103-1109, 2018. e-Pub 2018. PMID: 30311036.
- Yam, Murthy, Rauch, Murray, Walters. A Phase II STudy of Imatinib mesylate and letrozole in patients in hormone-receptor positive metastatic breast cancer expressing c-kit or PDGFR-beta. Investigational New Drugs 36(6):1103-1109, 2018. e-Pub 2018.
- Nardi EA, McCanney J, Winckworth-Prejsnar K, Schatz AA, Adelson K, Neubauer M, Smith ML, Walters R, Carlson RW. Redefining Quality Measurement in Cancer Care. J Natl Compr Canc Netw 16(5):473-478, 2018. e-Pub 2018. PMID: 29752321.
- Forum NQ. National Quality Forum Report on 2017 Activities to Congress and the Secretary of the Department of Health and Human Services, 2018. e-Pub 2018.
- Spinks T, Guzman A, Beadle B, Lee S, Jones D, Walters R, Incalcaterra J, Hanna E, Hessel A, Weber R, Denney S, Newcomer L, Feeley TW. Development and Feasibility of Bundled Payments for the Multidisciplinary Treatment of Head and Neck Cancer: A Pilot Program. Journal of Oncology Practice 14(2):103-112, 2018. e-Pub 2018.
- Forum NQ. MAP 2018 Considerations for Implementing Measures in Federal Programs: Hospital, 2018. e-Pub 2018.
- Forum NQ. 2016 Annual Report to Congress, 2017. e-Pub 2017.
- Forum NQ. 2017 Considerations for Implementing Measures Final Report - Hospitals, 2017. e-Pub 2017.
- Fayanju OM, Mayo TL, Spinks TE, Lee S, Barcenas CH, Smith BD, Giordano SH, Hwang RF, Ehlers RA, Selber JC, Walters R, Tripathy D, Hunt K, Buchholz TA, Feeley TW, Kuerer HM. Value Based Breast Cancer Care: A Multidisciplinary Approach for Defining Patient Centered Outcomes. Annals of Surgical Oncology 23(8):2385-90, 2016. e-Pub 2016.
- Forum NQ. NQF 2016 Report to Congress, 2016. e-Pub 2016.
- Forum NQ. MAP 2016 Considerations for Implementing Measures in Federal Programs - Hospitals, 2016. e-Pub 2016.
- Gonzalez CE, Johnson TN, Evans S, Kidin LM, George S, Haq S, DeJesus AY, Walters R, Rolston K. Assessing Compliance with Established Pneumonia Core Measures at a Comprehensive Cancer Center. Journal of Healthcare Quality 37(4):232-244, 2015. e-Pub 2015.
- Forum NQ. MAP Hospital Programmatic Deliverable: Final Report, 2015. e-Pub 2015.
- Quality Forum MAPN. Measuring Affordability from the Patient's Perspective, 2014. e-Pub 2014.
- Quality Forum MAPN. Finding Common Ground for Healthcare Priorities: Families of Measures for Assessing Affordability, Population Health, and Person-and Family-Centered Care, 2014. e-Pub 2014.
- Middleton LP, Feeley TW, Albright HW, Walters R, Hamilton SH. Second-opinion pathologic review is a patient safety mechanism that helps reduce error and decrease waste. J Oncol Pract 10(4):275-80, 2014. e-Pub 2014. PMID: 24695900.
- Quality Forum MAPN. NQF Report of 2013 Activities to Congress and the Secretary of the Department of Health and Human Services, 2014. e-Pub 2014.
- Walters RS. Opportunities for improvement: experience at one institution. J Natl Compr Canc Netw 12 Suppl 1:S36-9, 2014. e-Pub 2014. PMID: 24614051.
- Walters RS, Albright HW, Weber RS, Feeley TW, Hanna EY, Cantor SB, Lewis CM, Burke TW. Developing a system to track meaningful outcome measures in head and neck cancer treatment. Head Neck 36(2):226-30, 2014. e-Pub 2014. PMID: 23729280.
- Quality Forum MAPN. MAP 2014 Recommendations on Measures for More Than 20 Federal Programs, 2014. e-Pub 2014.
- Abdayem P, Ghosn M, Valero V, Walters R, Arun B, Murray JL, Theriault R, Frye D, Ibrahim NK. Phase I and II Study of Gemcitabine and Vinorelbine in Heavily Pretreated Patients with Metastatic Breast Cancer and Review of the Literature. J Cancer 5(5):351-9, 2014. e-Pub 2014. PMID: 24723978.
- Quality Forum MAPN. MAP Pre-rulemaking Report: 2013 Recommendations on Measures Under Consideration by HHS, 2013. e-Pub 2013.
- Quality Forum MAPN. NQF Report of Activities to Congress and the Secretary of the Department of Health and Human Services, 2013. e-Pub 2013.
- Quality Forum MAPN. MAP Families of Measures: Safety, Care Coordination, Cardiovascular Conditions, Diabetes, 2012. e-Pub 2012.
- Quality Forum MAPN. Performance Measurement Coordination Strategy for PPS Exempt Cancer Hospitals, 2012. e-Pub 2012.
- Kelly CM, Green MC, Broglio K, Thomas ES, Brewster AM, Valero V, Ibrahim NK, Gonzalez-Angulo AM, Booser DJ, Walters RS, Hunt KK, Hortobagyi GN, Buzdar AU. Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol 30(9):930-5, 2012. e-Pub 2012. PMID: 22331946.
- Quality Forum MAPN. Input on Measures Under Consideration by HHS for 2012 Rulemaking, 2012. e-Pub 2012.
- Quality Forum MAPN. Coordination Strategy for Healthcare-Acquired Conditions and Readmissions Across Public and Private Payers, 2011. e-Pub 2011.
- Tortorella FR, Ewer MS, Douglas-Ntagha PB, Harper G, Walters R, Ecung WB. Developing a transfer center in a tertiary cancer center: streamlining access and communication to accommodate increasing demand for service. J Healthc Manag 56(3):199-210; discussion 210-1, 2011. e-Pub 2011. PMID: 21714374.
- Spinks TE, Walters R, Feeley TW, Albright HW, Jordan VS, Bingham J, Bure TW. Improving Cancer Care Through Public Reporting of Meaningful Quality Measures. Health Affairs (Millwood) 30(4):664-672, 2011. e-Pub 2011.
- Arun BK, Dhinghra K, Valero V, Kau SW, Broglio K, Booser D, Guerra L, Yin G, Walters R, Sahin A, Ibrahim N, Buzdar AU, Frye D, Sneige N, Strom E, Ross M, Theriault RL, Vadhan-Raj S, Hortobagyi GN. Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist 16(11):1527-34, 2011. e-Pub 2011. PMID: 22042783.
- Feeley TW, Fly HS, Albright H, Walters R, Burke TW. A method for defining value in healthcare using cancer care as a model. J Healthc Manag 55(6):399-411; discussion 411-2, 2010. e-Pub 2010. PMID: 21166323.
- Taylor SH, WAlters R. Potential Impact of Tumor Registry Rule Changes for Recording Inflammatory Breast Cancer. Cancer 116(11(Suppl 1)):2745-7, 2010. e-Pub 2010.
- Rivera E, Mejia JA, Arun BK, Adinin RB, Walters RS, Brewster A, Broglio KR, Yin G, Esmaeli B, Hortobagyi GN, Valero V. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 112(7):1455-61, 2008. e-Pub 2008. PMID: 18300256.
- Beinart GA, Gonzalez-Angulo AM, Broglio K, Frye D, Walters R, Holmes FA, Gunale S, Booser D, Rosenthal J, Dhingra K, Young JA, Hortobagyi GN. Phase II trial of 10-EDAM in the treatment of metastatic breast cancer. Cancer Chemother Pharmacol 60(1):61-7, 2006. e-Pub 2006. PMID: 17009032.
- Gonzalez-Angulo AM, Walters RS, Carpenter RJ Jr, Ross MI, Perkins GH, Gwyn K, Theriault RL. Paclitaxel chemotherapy in a pregnant patient with bilateral breast cancer. Clin Breast Cancer 5(4):317-9, 2004. e-Pub 2004. PMID: 15507181.
- Thomas E, Holmes FA, Smith TL, Buzdar AU, Frye DK, Fraschini G, Singletary SE, Theriault RL, McNeese MD, Ames F, Walters R, Hortobagyi GN. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol 22(12):2294-302, 2004. e-Pub 2004. PMID: 15197190.
- Rivera E, Valero V, Arun B, Royce M, Adinin R, Hoelzer K, Walters R, Wade JL, rd, Pusztai L, Hortobagyi GN. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol 21(17):3249-54, 2003. e-Pub 2003. PMID: 12947059.
- Assikis V, Buzdar A, Yang Y, Smith T, Theriault R, Booser D, Valero V, Walters R, Singletary E, Ames F, Hortobagyi G. A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up. Cancer 97(11):2716-23, 2003. e-Pub 2003. PMID: 12767083.
- Buzdar AU, Singletary SE, Valero V, Booser DJ, Ibrahim NK, Rahman Z, Theriault RL, Walters R, Rivera E, Smith TL, Holmes FA, Hoy E, Frye DK, Manuel N, Kau SW, McNeese MD, Strom E, Thomas E, Hunt K, Ames F, Berry D, Hortobagyi GN. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res 8(5):1073-9, 2002. e-Pub 2002. PMID: 12006521.
- Rivera E, Holmes FA, Buzdar AU, Asmar L, Kau SW, Fraschini G, Walters R, Theriault RL, Hortobagyi GN. Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease. Breast J 8(1):2-9, 2002. e-Pub 2002. PMID: 11856154.
- Rivera E, Holmes FA, Frye D, Valero V, Theriault RL, Booser D, Walters R, Buzdar AU, Dhingra K, Fraschini G, Hortobagyi GN. Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy. Cancer 89(11):2195-201, 2000. e-Pub 2000. PMID: 11147589.
- Ibrahim NK, Valero V, Theriault RL, Willey J, Walters RS, Buzdar AU, Booser DJ, Hortobagyi GN. Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer. Am J Clin Oncol 23(2):117-21, 2000. e-Pub 2000. PMID: 10776969.
- Booser DJ, Walters RS, Holmes FA, Hortobagyi GN. Continuous-infusion high-dose leucovorin with 5-fluorouracil and cisplatin for relapsed metastatic breast cancer: a phase II study. Am J Clin Oncol 23(1):40-1, 2000. e-Pub 2000. PMID: 10683074.
- Valero V, Buzdar AU, Theriault RL, Azarnia N, Fonseca GA, Willey J, Ewer M, Walters RS, Mackay B, Podoloff D, Booser D, Lee LW, Hortobagyi GN. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol 17(5):1425-34, 1999. e-Pub 1999. PMID: 10334527.
- Holmes FA, Valero V, Walters RS, Theriault RL, Booser DJ, Gibbs H, Fraschini G, Buzdar AU, Willey J, Frye D, Asmar L, Hortobagyi GN. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results. Ann Oncol 10(4):403-11, 1999. e-Pub 1999. PMID: 10370782.
- Pusztai L, Walters RS, Valero V, Theriault RL, Hortobagyi GN. Daily oral etoposide in patients with heavily pretreated metastatic breast cancer. Am J Clin Oncol 21(5):442-6, 1998. e-Pub 1998. PMID: 9781596.
- Walters RS, Holmes FA, Valero V, Esparza-Guerra L, Hortobagyi GN. Phase II study of ifosfamide and mesna in patients with metastatic breast cancer. Am J Clin Oncol 21(4):413-5, 1998. e-Pub 1998. PMID: 9708645.
- Holmes FA, Madden T, Newman RA, Valero V, Theriault RL, Fraschini G, Walters RS, Booser DJ, Buzdar AU, Willey J, Hortobagyi GN. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 14(10):2713-21, 1996. e-Pub 1996. PMID: 8874332.
- Ibrahim NK, Frye DK, Buzdar AU, Walters RS, Hortobagyi GN. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Arch Intern Med 156(8):882-8, 1996. e-Pub 1996. PMID: 8774207.
- Theriault RL, Walters RS, Holmes FA, Esparza-Guerra L, Kowal C, Hortobagyi GN. A phase II study of CI-973 [SP-4-3(R)]-1,1-cyclobutane-dicarboxylato (2-)] (2-methyl-1,4-butanediamine-N, N') platinum in patients with refractory advanced breast cancer. Cancer Chemother Pharmacol 38(3):289-91, 1996. e-Pub 1996. PMID: 8646805.
- Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13(12):2886-94, 1995. e-Pub 1995. PMID: 8523051.
- Walters RS, Theriault RL, Booser DJ, Esparza L, Hortobagyi GN. Phase II study of recombinant alpha-interferon (rIFN alpha) and continuous-infusion 5-fluorouracil in metastatic breast cancer. J Immunother Emphasis Tumor Immunol 18(3):185-7, 1995. e-Pub 1995. PMID: 8770774.
- Dhingra K, Frye D, Newman RA, Walters R, Theriault R, Fraschini G, Smith T, Buzdar A, Hortobagyi GN. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. Clin Cancer Res 1(7):691-7, 1995. e-Pub 1995. PMID: 9816034.
- Walters RS, Theriault RL, Holmes FA, Esparza L, Hortobagyi GN. Phase II study of recombinant alpha-interferon and recombinant interleukin-2 metastatic breast cancer. J Immunother Emphasis Tumor Immunol 16(4):303-5, 1994. e-Pub 1994. PMID: 7881639.
- Buzdar AU, Kau S, Hortobagyi GN, Theriault RL, Booser D, Holmes FA, Walters R, Krakoff IH. Phase I trial of droloxifene in patients with metastatic breast cancer. Cancer Chemother Pharmacol 33(4):313-6, 1994. e-Pub 1994. PMID: 8281625.
- Valero, V, Esparza L, Holmes F, Walters R, Fraschini G, Theriault R, Dhingra K, Buzdar A, Bellet R, Slattery A, Pazdur R, Raber M, Bayssas M, Hortobagyi G. Phase II study of taxotere in refractory metastatic breast cancer (RMBC), . Proc Am Soc Clin Oncol 12:184, 1993. e-Pub 1993.
- Dhingra, K, Frye D, Newman RA, Walters R, Theriault R, Fraschini G, Smith T, Buzdar A, Hortobagyi G. Phase II study of 5-fluorouracil, pirarubicin and cyclophosphamide in metastatic breast cancer. J Clin Oncol, 1993. e-Pub 1993.
- Holmes FA, Valero V, Walters RS, Theriault RL, Booser DJ, Fraschini G, Buzdar AU, Frye D, Gibbs HR, Hortobagyi GN. The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. J Natl Cancer Inst Monogr(15):161-9, 1993. e-Pub 1993. PMID: 7912522.
- Dhingra, K, Esparza L, Valero V, Booser D, Walters R, Holmes F, Buzdar A, Hortobagyi G. Neoadjuvant chemotherapy (Chemo) of Breast cancer: Impact of G-CSF on received dose intensity (DI). Proc Am Soc Clin Oncol 132:182, 1993. e-Pub 1993.
- Benvenuto JA, Newman RA, Bignami GS, Raybould TJ, Raber MN, Esparza L, Walters RS. Phase II clinical and pharmacological study of didemnin B in patients with metastatic breast cancer. Invest New Drugs 10(2):113-7, 1992. e-Pub 1992. PMID: 1500265.
- Walters RS, Theriault RL, Holmes FA, Hortobagyi GN, Esparza L. Phase II trial of fazarabine (ARA-AC, arabinosyl-5-azacytosine) in metastatic breast cancer. Invest New Drugs 10(1):43-4, 1992. e-Pub 1992. PMID: 1376723.
- Walters RS, Frye D, Buzdar AU, Holmes FA, Hortobagyi GN. A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma. Cancer 69(2):476-81, 1992. e-Pub 1992. PMID: 1728377.
- Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83(24):1797-805, 1991. e-Pub 1991. PMID: 1683908.
- Fraschini G, Ciociola A, Esparza L, Templeton D, Holmes FA, Walters RS, Hortobagyi GN. Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy. J Clin Oncol 9(7):1268-74, 1991. e-Pub 1991. PMID: 1828499.
- Walters R, Kantarjian HM, Keating MJ, Estey EH, Trujillo J, Cork A, McCredie KB, Freireich EJ. The importance of cytogenetic studies in adult acute lymphocytic leukemia. Am J Med 89(5):579-87, 1990. e-Pub 1990. PMID: 2239977.
- Kantarjian HM, Walters RS, Keating MJ, Smith TL, O'Brien S, Estey EH, Huh YO, Spinolo J, Dicke K, Barlogie B, et al. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol 8(6):994-1004, 1990. e-Pub 1990. PMID: 2189958.
- Childs CC, Hirsch-Ginsberg C, Walters RS, Andersson BS, Reuben J, Trujillo JM, Cork A, Stass SA, Freireich EJ, Zipf TF. Myeloid surface antigen-positive acute lymphoblastic leukemia (My+ ALL): immunophenotypic, ultrastructural, cytogenetic, and molecular characteristics. Leukemia 3(11):777-83, 1989. e-Pub 1989. PMID: 2811478.
- Keating MJ, Kantarjian H, Smith TL, Estey E, Walters R, Andersson B, Beran M, McCredie KB, Freireich EJ. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 7(8):1071-80, 1989. e-Pub 1989. PMID: 2666590.
- Kantarjian HM, Walters RS, Keating MJ, Barlogie B, McCredie KB, Freireich EJ. Experience with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory acute lymphocytic leukemia. Cancer 64(1):16-22, 1989. e-Pub 1989. PMID: 2659160.
- Kantarjian HM, Keating MJ, Walters RS, Koller CA, McCredie KB, Freireich EJ. Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia. Cancer 63(5):813-7, 1989. e-Pub 1989. PMID: 2914287.
- Hittelman WN, Agbor P, Petkovic I, Andersson B, Kantarjian H, Walters R, Koller C, Beran M. Detection of leukemic clone maturation in vivo by premature chromosome condensation. Blood 72(6):1950-60, 1988. e-Pub 1988. PMID: 3196873.
- Kantarjian HM, Walters RS, Smith TL, Keating MJ, Barlogie B, McCredie KB, Freireich EJ. Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia. Blood 72(5):1784-9, 1988. e-Pub 1988. PMID: 3052630.
- Vadhan-Raj S, Kellagher MJ, Keating M, Walters R, Gutterman JU. Phase I study of recombinant human granulocyte-macrophage colony-stimulating factor in patients with bone marrow failure and malignancy. Behring Inst Mitt(83):119-24, 1988. e-Pub 1988. PMID: 2467646.
- Kantarjian HM, Walters RS, Keating MJ, Talpaz M, Andersson B, Beran M, McCredie KB, Freireich EJ. Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside. Cancer 62(4):672-6, 1988. e-Pub 1988. PMID: 3165046.
- Walters RS, Kantarjian HM, Keating MJ, Plunkett WK, Estey EH, Andersson B, Beran M, McCredie KB, Freireich EJ. Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia. Cancer 62(4):677-82, 1988. e-Pub 1988. PMID: 3165047.
- Vadhan-Raj S, Buescher S, LeMaistre A, Keating M, Walters R, Ventura C, Hittelman W, Broxmeyer HE, Gutterman JU. Stimulation of hematopoiesis in patients with bone marrow failure and in patients with malignancy by recombinant human granulocyte-macrophage colony-stimulating factor. Blood 72(1):134-41, 1988. e-Pub 1988. PMID: 3291976.
- Keating MJ, Smith TL, Kantarjian H, Cork A, Walters R, Trujillo JM, McCredie KB, Gehan EA, Freireich EJ. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia 2(7):403-12, 1988. e-Pub 1988. PMID: 3164797.
- Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB, Freireich EJ. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 61(7):1441-6, 1988. e-Pub 1988. PMID: 3162181.
- Amato R, Kantarjian H, Walters R, Keating M. Rebound peripheral blastosis with subsequent remission during remission induction in a patient with acute promyelocytic leukemia. Cancer 61(4):650-3, 1988. e-Pub 1988. PMID: 3422175.
- Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Freireich EJ. The characteristics and outcome of patients with late relapse acute myelogenous leukemia. J Clin Oncol 6(2):232-8, 1988. e-Pub 1988. PMID: 3276823.
- Childs CC, Hirsch-Ginsberg C, Culbert SJ, Ahearn M, Reuben J, Trujillo JM, Cork A, Walters RR, Freireich EJ, Stass SA. Lineage heterogeneity in acute leukemia with the t(4;11) abnormality: implications for acute mixed lineage leukemia. Hematol Pathol 2(3):145-57, 1988. e-Pub 1988. PMID: 3220802.
- Lee J, Talpaz M, Walters R, Gutterman JU, Blick M. Aberrant expression of the K-ras proto-oncogene in B-cell malignancies. Hematol Pathol 2(4):229-37, 1988. e-Pub 1988. PMID: 3075608.
- Heinemann V, Murray D, Walters R, Meyn RE, Plunkett W. Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine. Cancer Chemother Pharmacol 22(3):205-10, 1988. e-Pub 1988. PMID: 3165725.
- Kantarjian H, Walters R. Implications of cytogenetic findings in secondary leukemia. Am J Clin Oncol 10(5):453-6, 1987. e-Pub 1987. PMID: 3477944.
- Walters RS, Kantarjian HM, Keating MJ, Talpaz M, Childs CC, McCredie KB, Freireich EJ. Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuous vincristine and adriamycin infusions plus high-dose decadron. Cancer 60(8):1708-12, 1987. e-Pub 1987. PMID: 3477315.
- Kurzrock R, Talpaz M, Kantarjian H, Walters R, Saks S, Trujillo JM, Gutterman JU. Therapy of chronic myelogenous leukemia with recombinant interferon-gamma. Blood 70(4):943-7, 1987. e-Pub 1987. PMID: 3115339.
- Kantarjian HM, Keating MJ, McCredie KB, Walters R, Talpaz M, Smith TL, Freireich EJ. Old age: a sign of poor prognosis in patients with chronic myelogenous leukemia. South Med J 80(10):1228-32, 1987. e-Pub 1987. PMID: 3477869.
- Kurzrock R, Shtalrid M, Gutterman JU, Koller CA, Walters R, Trujillo JM, Talpaz M. Molecular analysis of chromosome 22 breakpoints in adult Philadelphia-positive acute lymphoblastic leukaemia. Br J Haematol 67(1):55-9, 1987. e-Pub 1987. PMID: 3478080.
- Kantarjian HM, Keating MJ, Talpaz M, Walters RS, Smith TL, Cork A, McCredie KB, Freireich EJ. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med 83(3):445-54, 1987. e-Pub 1987. PMID: 3477958.
- Walters RS, Kantarjian HM, Keating MJ, Estey EH, McCredie KB, Freireich EJ. Intensive treatment of acute leukemia in adults 70 years of age and older. Cancer 60(2):149-55, 1987. e-Pub 1987. PMID: 3474052.
- Kurzrock R, Kloetzer WS, Talpaz M, Blick M, Walters R, Arlinghaus RB, Gutterman JU. Identification of molecular variants of p210bcr-abl in chronic myelogenous leukemia. Blood 70(1):233-6, 1987. e-Pub 1987. PMID: 2885048.
- Keating MJ, Gehan EA, Smith TL, Estey EH, Walters RS, Kantarjian HM, McCredie KB, Freireich EJ. A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia. J Clin Oncol 5(5):710-21, 1987. e-Pub 1987. PMID: 3553435.
- Kantarjian HM, Keating MJ, Walters RS, Smith TL, McCredie KB, Freireich EJ. Role of maintenance chemotherapy in acute promyelocytic leukemia. Cancer 59(7):1258-63, 1987. e-Pub 1987. PMID: 3469011.
- Kurzrock, R, Talpaz M, Kantarjian H, Walters R, Saks S, Trujillo JM, Gutterman JU. Clinical investigation or recombinant interferongamma in chronic myelogenous leukemia. Blood 70(4):943-947, 1987. e-Pub 1987.
- Dicke KA, Jagannath S, Walters RS, Horwitz LJ, Spitzer G. The role of autologous bone marrow transplantation in acute leukemia. Ann N Y Acad Sci 511:468-72, 1987. e-Pub 1987. PMID: 3326476.
- Keating MJ, Cork A, Broach Y, Smith T, Walters RS, McCredie KB, Trujillo J, Freireich EJ. Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia. Leuk Res 11(2):119-33, 1987. e-Pub 1987. PMID: 3469482.
- Keating MJ, Estey E, Kantarjian HM, Walters R, Smith T, McCredie KB, Freireich EJ. Comparison of results of salvage therapy in adult acute myelogenous leukemia. Acta Haematol 78 Suppl 1:120-6, 1987. e-Pub 1987. PMID: 3124434.
- Kantarjian HM, Keating MJ, Walters RS, Smith TL, Cork A, McCredie KB, Freireich EJ. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol 4(12):1748-57, 1986. e-Pub 1986. PMID: 3783201.
- Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Smith TL, Talpaz M, Beran M, Cork A, Trujillo JM, Freireich EJ. Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia. Cancer 58(9):2023-30, 1986. e-Pub 1986. PMID: 3463397.
- Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Bodey GP, Freireich EJ. Early intensification and short-term maintenance chemotherapy does not prolong survival in acute myelogenous leukemia. Cancer 58(8):1603-8, 1986. e-Pub 1986. PMID: 3463390.
- Kantarjian HM, Estey EH, Plunkett W, Keating MJ, Walters RS, Iacoboni S, McCredie KB, Freireich EJ. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am J Med 81(3):387-94, 1986. e-Pub 1986. PMID: 3463209.
- Kantarjian HM, Keating MJ, Walters RS, Beran M, McLaughlin P, McCredie KB, Freireich EJ. The association of specific "favorable" cytogenetic abnormalities with secondary leukemia. Cancer 58(4):924-7, 1986. e-Pub 1986. PMID: 3719557.
- Jones PG, Rolston KV, Fainstein V, Elting L, Walters RS, Bodey GP. Aztreonam therapy in neutropenic patients with cancer. Am J Med 81(2):243-8, 1986. e-Pub 1986. PMID: 3526885.
- Kantarjian HM, Keating MJ, Walters RS, Estey EH, McCredie KB, Smith TL, Dalton WT, Jr, Cork A, Trujillo JM, Freireich EJ. Acute promyelocytic leukemia. M.D. Anderson Hospital experience. Am J Med 80(5):789-97, 1986. e-Pub 1986. PMID: 3458366.
- Kantarjian HM, Smith TL, McCredie KB, Keating MJ, Walters RS, Talpaz M, Hester JP, Bligham G, Gehan E, Freireich EJ. Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood 66(6):1326-35, 1985. e-Pub 1985. PMID: 3864497.
- Keating MJ, Estey E, Plunkett W, Iacoboni S, Walters R, Kantarjian H, Andersson B, Beran M, McCredie KB, Freireich EJ. Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital. Semin Oncol 12(2 Suppl 3):98-104, 1985. e-Pub 1985. PMID: 3859935.
- Kantarjian HM, Keating MJ, McCredie KB, Beran M, Walters R, Dalton WT, Jr, Hittleman W, Freireich EJ. A characteristic pattern of leukemic cell differentiation without cytoreduction during remission induction in acute promyelocytic leukemia. J Clin Oncol 3(6):793-8, 1985. e-Pub 1985. PMID: 3859586.
- Estey EH, Keating MJ, Smith TL, McCredie KB, Legha SS, Walters RS, Bodey GP, Freireich EJ. Prediction of complete remission in patients with refractory acute leukemia treated with AMSA. J Clin Oncol 2(2):102-6, 1984. e-Pub 1984. PMID: 6583328.
- Talpaz M, Mavligit G, Keating M, Walters RS, Gutterman JU. Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia. Ann Intern Med 99(6):789-92, 1983. e-Pub 1983. PMID: 6580836.
Invited Articles
- Forum NQ. National Quality Partners Case Study Integrating Personal Preferences in Advanced Illness Care, 2017. e-Pub 2017.
- Walters RS. Opportunities for Improvement: Experience at One Institution. Journal of the National Comprehensive Cancer Network 12(Suppl 1):S36-39, 2014. e-Pub 2014.
Review Articles
- Glance LG, Joynt Maddox K, Johnson K, Nerenz D, Cella D, Borah B, Kunisch J, Kurlansky P, Perloff J, Stoto M, Walters R, White S, Lin Z. National Quality Forum Guidelines for Evaluating the Scientific Acceptability of Risk-adjusted Clinical Outcome Measures: A Report From the National Quality Forum Scientific Methods Panel. Ann Surg 271(6):1048-1055, 2020. e-Pub 2020. PMID: 31850998.
- Johnson T, Bandini LAM, Martin K, Jones L, Carlson J, Walters RS, Carlson RW. The State of Cancer Care in America: Impact of State Policy on Access to High-Quality Cancer Care. J Natl Compr Canc Netw 18(4):400-404, 2020. e-Pub 2020. PMID: 32259786.
- D'Amico TA, Bandini LAM, Balch A, Benson AB, Edge SB, Fitzgerald CL, Green RJ, Koh WJ, Kolodziej M, Kumar S, Meropol NJ, Mohler JL, Pfister D, Walters RS, Carlson RW. Quality Measurement in Cancer Care: A Review and Endorsement of High-Impact Measures and Concepts. J Natl Compr Canc Netw 18(3):250-259, 2020. e-Pub 2020. PMID: 32135508.
- Albright HW, Moreno M, Feeley TW, Walters R, Samuels M, Pereira A, Burke TW. The implications of the 2010 Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act on cancer care delivery. Cancer 117(8):1564-74, 2011. e-Pub 2011. PMID: 21472704.
- Weingart SN, Brown E, Bach PB, Eng K, Johnson SA, Kuzel TM, Langbaum TS, Leedy RD, Muller RJ, Newcomer LN, O'Brien S, Reinke D, Rubino M, Saltz L, Walters RS. NCCN Task Force Report: Oral chemotherapy. J Natl Compr Canc Netw 6 Suppl 3:S1-14, 2008. e-Pub 2008. PMID: 18377852.
- Anderson CM, Walters RS, Hortobagyi GN. Mediastinitis related to probable central vinblastine extravasation in a woman undergoing adjuvant chemotherapy for early breast cancer. Am J Clin Oncol 19(6):566-8, 1996. e-Pub 1996. PMID: 8931672.
Other Articles
- Forum NQ National Quality Partners Action Brief: Shared Decision Making A Standard of Care for All Patients, 2017.
Abstracts
- Willey, J, Ibrahim NK, Walters R, Rahman Z, Valero V, Esteva FJ, Hortobagyi GN. Vocal cord paralysis secondary to biweekly vinorelbine (NVB; Navelbine) and paclitaxel (PTX; Taxol) by simultaneous 3-hour (H) infusion (inf) with G-CSF support as frontline therapy for metastatic breast cancer (MBC) patients (pts). . Proc Annu Meet Am Soc Clin Oncol 17:A704, 1998. e-Pub 1998.
- Holmes, FA, Valero V, Walters R, Buzdar AU, Booser DJ, Winn R, Tolcher A, Seidman A, Goodwin W, Bearden J, Whealin H, Hortobagyi GN. Phase III trial of paclitaxel (P) administered over 3- or 96-hr for metastatic breast cancer (MBC). . Proc Annu Meet Am Soc Clin Oncol 15:A91, 1996. e-Pub 1996.
Book Chapters
- Hagberg, CA, Gottumukkala, V, Riedel, B, Nates, J, Buggy, D. Economics of Cancer Care Delivery: Opportunities and Challenges. In: Perioperative Care of the Cancer Patient. Elsevier, 589-593, 2023.
- Raber MN, Walters RS. Delivering High-Quality Cancer Care in a Changing Health Care Environment. In: Holland-Frei Cancer Medicine, 7th Edition. B.C. Decker, Inc, 1031-1034, 2006.
- Holmes, FA, Valero V, Walters R, Theriault R, Booser D, Buzdar A, Gibbs H, Frye D, Young K, Hortobagyi G. Taxol in metastatic breast cancer: the MD Anderson Cancer Center experience. In: Cancer Treatment: An Update. Springer-Verlag, 1994.
- Valero, V, Theriault R, Esparza L, Fraschini G, Holmes F, Walters R, Buzdar A, Raber M, Pazdur R, Bellet R, Bayssas M, Hortobagyi GN. Phase II study of taxotere in patients with anthracycline-resistant metastatic breast cancer. In: Recent Advances in Chemotherapy: Proceedings of the 18th International Congress of Chemotherapy, 844-845, 1994.
- Walters, RS, Johnston DA, Dixon DO, Stass SA, Keating MJ, Trujillo JM, McCredie KB, Barlogie B. Nucleic acid flow cytometry - an aid to diagnosis and prognosis in acute leukemia in adults. In: The Acute Leukemias: Biologic, Diagnostic, and Therapeutic Determinants. Marcel Dekker, Inc, 1987.
Patient Reviews
CV information above last modified July 22, 2026